This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.
Has subjective or objective cognitive impairment
Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member)
Sufficient proficiency in English or French to undertake self report and neuropsychological testing
Geographic accessibility to the study site
The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses
Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
Symptomatic stroke within the previous year
Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure
8
Trial groupsSee each trial group below.
McGill University
Lead sponsor
Baycrest
Sponsor institution
Canadian Institutes of Health Research (CIHR)
Collaborator
Alzheimer Society of Canada
Collaborator
Sanofi
Collaborator
New Brunswick Health Research Foundation
Collaborator
Saskatchewan Health Research Foundation
Collaborator
Michael Smith Foundation for Health Research
Collaborator
Nova Scotia Health Research Foundation
Collaborator
Eli Lilly and Company
Collaborator
Canadian Nurses Foundation (CNF)
Collaborator
Ontario Brain Institute
Collaborator
Pfizer
Collaborator
Canadian Consortium on Neurodegeneration in Aging
Collaborator